Haemate P (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemate P is indicated for the management of bleeding in patients with specific clotting factor deficiencies.

• Treatment of acute bleeding episodes in hemophilia A patients.
• Routine prophylaxis to prevent spontaneous bleeds in hemophilia A.
• Management of bleeding episodes in von Willebrand disease, especially type 3.
• Surgical or invasive procedure support in patients with factor VIII or von Willebrand factor deficiency.
• Peri‑operative hemostasis for patients undergoing major surgery.

Adverse reactions reported with Haemate P vary in frequency and severity.

Common

• Mild headache.
• Fever or chills.
• Infusion site erythema or pain.
• Nausea.
• Transient hypertension.
• Fatigue.

Serious

• Anaphylactic or severe hypersensitivity reactions.
• Development of inhibitors (antibodies) to factor VIII.
• Thromboembolic events.
• Severe hemolysis.
• Acute renal failure.

Before initiating therapy with Haemate P, clinicians should consider several safety considerations.

• Assess for a history of allergic reactions to plasma‑derived products.
• Screen for inhibitors to factor VIII prior to treatment.
• Monitor for signs of thrombosis, especially in patients with cardiovascular risk factors.
• Use caution in patients with renal or hepatic impairment.
• Avoid use in patients with uncontrolled hypertension.
• Evaluate pregnancy and lactation status, as safety data are limited.

Haemate P may interact with other medications that affect hemostasis or immune response.

Avoid

• Concomitant use of other factor concentrates without medical supervision.
• High‑dose pro‑coagulant agents (e.g., activated prothrombin complex concentrate) that increase thrombosis risk.

Use with caution

• Antifibrinolytic agents such as tranexamic acid.
• Immunosuppressive drugs that may alter inhibitor development.
• Certain antibiotics (e.g., beta‑lactams) that can cause hypersensitivity.